Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics Corporation (Nasdaq: UTHR) will have its CEO, Dr. Martine Rothblatt, present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020. The session will run from 11:40 a.m. to 12:20 p.m. EDT and will be accessible via a live webcast on the company's website. An archived version will be available 24 hours post-session for 90 days. United Therapeutics is dedicated to innovation in biotechnology, focusing on organ transplant technologies through its subsidiary, Lung Biotechnology PBC, which aims to address organ shortages.
United Therapeutics Corporation (Nasdaq: UTHR) appointed Dr. Linda Maxwell as an independent director on September 10, 2020. Dr. Maxwell, a distinguished head and neck surgeon and healthcare innovator, brings extensive expertise in medical education and health technology entrepreneurship. She has held significant positions in various academic institutions and has experience managing startups in clinical development. United Therapeutics emphasizes the value of her achievements in advancing human health and innovative approaches in biotechnology.
United Therapeutics Corporation (Nasdaq: UTHR) announced that the FDA accepted its supplemental New Drug Application for Tyvaso® (treprostinil) Inhalation Solution, targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD). This potential approval would make Tyvaso the first treatment for about 30,000 affected patients in the U.S. The FDA review is expected to conclude in April 2021, based on positive results from the phase 3 INCREASE study, which demonstrated significant improvements in 6-minute walk distance and secondary endpoints.
United Therapeutics Corporation (Nasdaq: UTHR) announced an upcoming fireside chat on August 11, 2020, from 8:00 to 8:30 a.m. EDT, at the Wedbush PacGrow Healthcare Virtual Conference. Dr. Martine Rothblatt, the company's CEO, will provide an overview and update on their business strategy. The presentation can be accessed live on the United Therapeutics website, with an archived version available for 90 days post-event. The company focuses on innovative solutions for transplantable organs through its subsidiary, Lung Biotechnology PBC.
United Therapeutics Corporation (Nasdaq: UTHR) reported second-quarter 2020 results, revealing revenues of $362.0 million, down 3% from $373.6 million in 2019. Net income plummeted 48% to $107.1 million, with earnings per diluted share falling to $2.41. Despite challenges, including a 24% revenue drop for Remodulin due to generic competition and pandemic issues, Orenitram sales surged 40% following a label update. The company anticipates product launches in the near term, although certain projects face delays due to COVID-19-related disruptions.
United Therapeutics Corporation (Nasdaq: UTHR) announced a new patent for Tyvaso (treprostinil) Inhalation Solution, issued July 21, 2020, expiring May 14, 2027. This patent, U.S. Patent No. 10,716,793, includes claims for the dosing regimen of Tyvaso. The company has filed an amended complaint against Liquidia Technologies for patent infringement related to this new patent, amidst ongoing litigation over Liquidia's NDA for LIQ861. United Therapeutics aims to enforce its intellectual property rights, although the unpredictability of litigation presents risks.
United Therapeutics Corporation (Nasdaq: UTHR) plans to release its second quarter 2020 financial results on July 29, 2020, before the market opens. Following the announcement, a teleconference will be held at 9:00 a.m. Eastern Time, which can be accessed via phone or web. The company emphasizes its commitment to innovation and quality, with a particular focus on expanding the supply of transplantable organs through its subsidiary, Lung Biotechnology PBC. The release contains forward-looking statements that are subject to risks and uncertainties.
United Therapeutics Corporation (Nasdaq: UTHR) is set to present data from the INCREASE study on Tyvaso® (treprostinil) Inhalation Solution for pulmonary hypertension associated with interstitial lung disease at the American Thoracic Society's session on June 24, 2020. The phase III trial showed a significant increase in six-minute walk distance by 21 meters compared to placebo (p=0.0043) after 16 weeks and improvements in secondary endpoints, including biomarkers. The company has submitted a supplemental New Drug Application to the FDA to update the Tyvaso label with these findings.